Skip to main content

Table 1 Clinical characteristics of the patients with rheumatoid arthritis a from the discovery collection

From: Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

Features All patients Infliximab Adalimumab
Patients, number (%)a 205 151 (73.7) 54 (26.3)
Female (%) 83.4 85.4 77.8
Age at diagnosis, median (IQR) 47 (38 to 55) 47 (37 to 55) 48 (40 to 56)
Diagnosis to anti-TNF, median (IQR) 6 (3 to 12) 6 (3 to 12) 6 (2 to 11)
RF, % 74.5 74.7 74.1
ACPA, % 75.7 75.4 76.9
Erosive arthritis, % 84.9 83.5 88.9
Smoking, % 13.9 11.8 20.0
DMARDs before anti-TNF, mean ± SD 2.5 ± 1.2 2.5 ± 1.2 2.6 ± 1.1
Concomitant DMARDs (%) 97.5 98.0 96.3
Baseline ESR, median (IQR)b 34 (19 to 54) 34 (19 to 53) 34 (19 to 57)
Baseline CRP (mg/L), median (IQR)b 11.5 (5.5 to 23.9) 11.5 (5.5 to 23.9) 14.3 (5.5 to 23)
Baseline HAQ, median (IQR)b 1.5 (1.0 to 2.0) 1.5 (1.0 to 2.0) 1.4 (1.0 to 2.0)
DAS28, (mean ± SD)    
 baseline 5.9 ± 1.2 5.9 ± 1.1 5.9 ± 1.4
 three months 3.9 ± 1.4 4.0 ± 1.5 3.5 ± 1.1
 six months 3.8 ± 1.4 4.0 ± 1.5 3.4 ± 1.2
 twelve months 3.7 ± 1.5 3.8 ± 1.5 3.4 ± 1.6
EULAR response, %    
 three months    
  responder 30.4 28.7 34.6
  moderate 50.8 50.4 51.9
  no-responder 18.8 20.9 13.5
 six months    
  responder 32.8 32.1 34.8
  moderate 43.5 40.7 52.2
  no-responder 23.7 27.1 13.0
 twelve months    
  responder 43.5 40.2 51.1
  moderate 35.1 40.2 23.4
  no-responder 21.4 19.6 25.5
  1. aOnly patients with successful genotypes are included; bdata from <85% of patients: 157 for baseline ESR, 126 for baseline CRP and 171 for baseline HAQ. ACPA = anti-cyclic citrullinated peptides; CRP = C-reactive protein; DAS28 = Disease Activity Score 28; DMARD = disease modifying anti-rheumatic drugs; ESR = erythrocyte sedimentation rate; EULAR = European League Against Rheumatism; HAQ = Health Assessment Questionnaire; IQR = interquartile range; RF = rheumatoid factor; SD = standard deviation.